600518.SH
Kangmei Pharmaceutical Co., Ltd.
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 1.26
+0.00%Oct 30, 2026, 08:32 UTC
The opposing party appealed in the Zhengzhong Zhujiang case.
Source:Oct 30, 2026, 08:32 UTC
Kangmei Pharmaceutical reported third-quarter 2026 revenue of 1.237 billion yuan, down 10.51% year over year, and net profit attributable to shareholders of 57.3737 million yuan; for the first three quarters, revenue was 3.527 billion yuan, down 10.91%, net profit was 93.4085 million yuan, up 614.01%, and adjusted net loss was 33.7576 million yuan.
Source:Oct 30, 2026, 08:32 UTC
A court of first instance ruled in Kangmei Pharmaceutical's recourse-right dispute that Ma Xingtian and Xu Dongjin must pay 1.396 billion yuan in compensation.
Source:Oct 28, 2026, 09:21 UTC
Kangmei Pharmaceutical plans to repurchase shares for RMB 100 million to RMB 200 million for an employee shareholding plan or equity incentives.
Source:Aug 25, 2026, 09:09 UTC
Kangmei Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 36.0348 million yuan, up 113.21% year-on-year, while revenue fell 11.13% to 2.29 billion yuan.
Source:Aug 21, 2026, 07:39 UTC
Kangmei Pharmaceutical's chairman Lai Zhijian resigned from his positions as chairman, director, and legal representative, and Ou Guoxiong was appointed to act as chairman and legal representative.
Jul 20, 2026, 08:50 UTC
Kangmei Pharmaceutical received first-instance judgments in two recovery lawsuits, with the court ordering Ma Xingtian, Xu Dongjin, Qiu Xiwei, and Zhengzhong Zhujiang to pay compensation.